Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of M7824 monotherapy in biliary tract cancer after platinum-based chemotherapy
2018-003707-19Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bintrafusp alfa in biliary cancer, sponsored by Merck KGaA. Primary endpoint: Confirmed objective response rate (ORR). Started Jan 2019; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
biliary cancer
Beyond the preview
Go deeper on 2018-003707-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003707-19.